Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for ...
AZD0486 New Therapy for Relapsed B-cell Lymphoma - HealthTree for Lymphoma
AZD0486 for Acute Lymphoblastic Leukemia Clinical Trial 2024 | Power
AZD0486 (Suvatomib) Shows Strong Efficacy and Safety in Relapsed ...
AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma ...
AstraZeneca’s Promising Study on AZD0486 for B-Cell Malignancies: What ...
Early SYRUS Data Highlight Safety, Efficacy of AZD0486 in Relapsed ...
AZD0486 Demonstrates Early Efficacy for R/R DLBCL With Manageable ...
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
SYRUS Study Explores AZD0486 Safety, Dosing in Relapsed/Refractory B ...
The SOUNDTRACK-E trial: investigating AZD0486 in CLL, MCL, and DLBCL ...
AZD0486 Cycle #13 #14 #15/ 다섯 번째 중간검사/ 장애연금 등급 하락 : 네이버 블로그
SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PATIENTS ...
AZD0486 - Dressing Table/Stool/Waln
ASH 2024: Dr. Sameh Gaballa, MD on High Response Rates with AZD0486 in ...
AZD0486 Cycle #5/ 떨리는 중간검사/ PET CT 결과 : 네이버 블로그
Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh ...
阿斯利康13亿美元收购CD19/CD3双抗，AZD0486首次国内申报临床 - 知乎
阿斯利康CD19/CD3双抗在华申报临床 12月15日，CDE官网公示，AstraZeneca的AZD0486申报临床，旨在评估AZD0486 ...
阿斯利康「CD19/CD3双抗」在华获批临床 - 知乎
Foresight CLARITY™ Clinical Applications | Foresight Resources
TCE双抗治疗自免疾病的在研竞争格局：以CD19/CD20为主（截至2024年11月底） - 2024年12月 - - 小牛行研
阿斯利康CD19 × CD3双抗AZD0486在中国获批临床，针对白血病！
surovatamig (AZD0486) / AstraZeneca
4 ng AZD0486治厅R/RF恶者CR达85%，0RR为95% - 2024年12月 - 行业研究数据 - 小牛行研
AZ, 혈액암 이중항체 'AZD0486'…B세포 비호지킨 림프종 2상 승인
Exposure-Response Analysis and Quantitative Systems Pharmacology ...
CD3亲和力微调：抗肿瘤活性与安全性之间的理想平衡-TCE研发-德泰生物
阿斯利康 9 款 1 类新药在中国获批临床，多款国内进度位于第一梯队
ASH 2023 Insights: "Efficacy of Double Step-Up Dosing of AZD0486, a ...
Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates ...
Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed ...
The safety and efficacy of surovatamig (AZD0486) in R/R DLBCL: findings ...
阿斯利康最新财报：后期研发管线包含10款潜在重磅药物（附PPT）_新浪财经_新浪网
Paper: Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in ...
AZD0486详细的药物介绍、临床试验阶段和入排标准
Safety and efficacy of surovatamig (AZD0486) in adolescent and adult ...
2024年全球制药巨头研发投入TOP10
An ongoing Phase I study of AZD0486, a novel CD19xCD3 bispecific ...
The bispecific antibody AZD0486: an overview of the clinical journey to ...
Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in ...
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed ...
SYRUS phase I/II trial: Safety and efficacy of surovatamig (AZD0486) in ...
[ASH 2024]CD19xCD3 이중 T세포 관여제 'AZD0486', CAR-T 내성 림프종서 완전관해 29%
[ASH 2024] Photo News: 30,000 global experts gather in San Diego to ...
Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a ...
Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS ...
At the 65th American Society of Hematology (ASH) Annual Meeting and ...
[ASH 2023] Blood disorder innovators highlight latest progress at US meet
EHA24: Updated Results on the AZD-0486 Trial for Treating Relapsed ...
阿斯利康：CD3/CD19双抗启动自免一期临床 Armstrong 2025年10月1日， 阿斯利康 在Clinicaltrials.gov ...
Daum 카페
Oncology/Hematology articles page [1] | MedPage Today
A double step-up dosing approach to decrease toxicity of AZD0486, a ...
OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in ...
阿斯利康「CD19/CD3双抗」在华获批临床 研究开发 | 华源医药网
CD19阳性滤泡性淋巴瘤新药临床试验：CD19/CD3双抗AZD0486_细胞_受试者_研究
Surovatamig - Drug Targets, Indications, Patents - Synapse
:%0A%0AAZD0486%20for%20Acute%20Lymphoblastic%20Leukemia.png?md=1)
